UNSPSC 51183108: Glypinamide

This classification denotes an anti-diabetic agent with the molecular formula C13H18ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) ORE084U8IP, chemically known as urea, 1-((p-chlorophenyl)sulfonyl)-3-(hexahydro-1h-azepin-1-yl)- but more generally known as glypinamide, which bears US NIH Compound Identifier 219111. European Medicines Agency schedules Glypinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07956MIG.

UNSPSC 51183108 Glypinamide, a Commodity code, encompasses the procurement of specific pharmaceutical active ingredients and their formulated products by state and local health systems, purchasing cooperatives, and public health agencies. State and local governments acquire glypinamide-containing drugs through cooperative purchasing frameworks and direct pharmaceutical supply contracts to support public health facilities, correctional institutions, and Medicaid-eligible populations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and similar state-administered purchasing groups are the primary issuing bodies under this code, aggregating demand across multiple participating jurisdictions to negotiate volume pricing with manufacturers and authorized pharmaceutical wholesalers. Solicitations emphasize FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and structured pricing formats negotiated through authorized distributors, with performance metrics tied to supply chain reliability, reporting accuracy, and customer-service standards.

MMCAP's January 2026 Request for Proposal for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, represents current activity under this code. That solicitation covers multiple states including Minnesota and Oregon, with awarded vendors required to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with contract terms effective July 1, 2026. Evaluation criteria weight price competitiveness at 75 percent, with remaining points allocated to fixed pricing, administrative compliance, EDI capability, and administrative-fee acceptance. Vendors must maintain minimum insurance including $5,000,000 commercial general liability and demonstrate contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place. No specific award value is disclosed; however, all vendors pay a 3 percent administrative fee on purchases and face performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials.